Dash Bio, a Newton, MA-based innovator in tech-enabled services for drug development, raised $6.5M in Seed funding.
The round was led by Freestyle Capital, with participation from Swift Ventures, LifeX Ventures, and other private investors.
The company intends to use the funds to expand operations and its development efforts.
Dash Bio takes a technology-first approach to developing critical services across the drug development lifecycle. The company is building new capabilities that leverage AI, robotics, and fully-integrated software to fundamentally reinvent the way drugs are brought to market. Their first capability is a highly-automated clinical bioanalysis lab that promises to deliver GLP-compliant services.
Founders include:
- Dave Johnson(CEO),
- Ander Tallett (COO),
- Ely Porter
FinSMEs
24/10/2024